We also noted significantly reduced accumulation of tumor-infiltrating CD11b+Gr1+ cells (40.1 ± 8.3% vs. 11.0 ± 3.8% among CD45+ cells for control and sJAG1-treated groups, respectively), and increased IFN-γ production by lymphoid cells (Fig. 6f). The gene discussed is ITGAM; the disease is neoplasm.